NCT00623259View on ClinicalTrials.gov

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions
HIV Infections
Interventions
BIOLOGICAL

MVA-mBN120B

Trial Locations (1)

63110

Washington University, St Louis

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT00623259 - Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects | Biotech Hunter | Biotech Hunter